Research Progress of PCSK9 Inhibitors in Lipid-Lowering Therapy
-
Published:2023
Issue:08
Volume:13
Page:13414-13419
-
ISSN:2161-8712
-
Container-title:Advances in Clinical Medicine
-
language:
-
Short-container-title:ACM
Publisher
Hans Publishers
Subject
General Engineering
Reference36 articles.
1. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel
2. Ference, B.A., Ginsberg, H.N., Graham, I., et al. (2017) Low-Density Lipoproteins Cause Atherosclerotic Cardiovascular Disease. 1. Evidence from Genetic, Epidemiologic, and Clinical Studies. A Consensus Statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal, 38, 2459-2472.
3. Resistance and intolerance to statins
4. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment
5. Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field?